Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Comparing the efficacy of tisa-cel and axi-cel in patients with R/R FL

Michael Dickinson • 11 Jun 2022
EHA 2022
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Tisagenlecleucel
ELARA ZUMA-5

In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, compares the safety and efficacy of tisagenlecleucel (tisa-cel) versus axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) follicular lymphoma (FL) based on data from two pivotal clinical trials: ELARA (NCT03568461) and ZUMA-5 (NCT03105336). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Funding, research & consulting: Novartis, Roche, Kite/Gilead, BMS, Takeda

More from Michael Dickinson

The GOlDiLOX trial: pirtobrutinib plus glofitamab in MCL with previous covalent BTKi exposure 4:40
The GOlDiLOX trial: pirtobrutinib plus glofitamab in MCL with previous covalent BTKi exposure
Michael Dickinson • 13 Jun 2025
Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179 5:59
Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179
Michael Dickinson • 7 Dec 2024
A Phase I study of glofitamab plus a novel CD19 x CD28 costimulatory agonist in R/R B-NHL 3:56
A Phase I study of glofitamab plus a novel CD19 x CD28 costimulatory agonist in R/R B-NHL
Michael Dickinson • 7 Dec 2024
AEs physicians should look out for when treating R/R DLBCL with bispecific antibodies 5:50
AEs physicians should look out for when treating R/R DLBCL with bispecific antibodies
Michael Dickinson • 7 Dec 2024

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals